The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes

[1] Mulnier HE(1998)Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837-853

[2] Seaman HE(2006)Mortality in people with type 2 diabetes in the UK Diabet Med 23 516-521

[3] Raleigh VS(2011)Diabetes mellitus, fasting glucose, and risk of cause-specific death N Engl J Med 364 829-841

[4] Soe-damah-Muthu SS(2008)10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 1577-1589

[5] Colhoun HM(2004)Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 685-696

[6] Lawrenson RA(1998)Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 Br Med J 317 703-713

[7] Seshasai SR(2012)Heart disease and stroke statistics–2012 update: a report from the American Heart Association Circulation 125 e2-e220

[8] Kaptoge S(1999)The health care costs of heart failure in Sweden J Intern Med 246 275-284

[9] Thompson A(2009)Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia 52 2288-2298

[10] Holman RR(2010)New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR) J Intern Med 268 471-482

[1] Mulnier HE(1998)Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837-853

[2] Seaman HE(2006)Mortality in people with type 2 diabetes in the UK Diabet Med 23 516-521

[3] Raleigh VS(2011)Diabetes mellitus, fasting glucose, and risk of cause-specific death N Engl J Med 364 829-841

[4] Soe-damah-Muthu SS(2008)10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 1577-1589

[5] Colhoun HM(2004)Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 685-696

[6] Lawrenson RA(1998)Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 Br Med J 317 703-713

[7] Seshasai SR(2012)Heart disease and stroke statistics–2012 update: a report from the American Heart Association Circulation 125 e2-e220

[8] Kaptoge S(1999)The health care costs of heart failure in Sweden J Intern Med 246 275-284

[9] Thompson A(2009)Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia 52 2288-2298

[10] Holman RR(2010)New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR) J Intern Med 268 471-482